Table 1. Study characteristics, patient population.
Name, year | Diagnosis in the study population | Design | Consecutive | n (Eyes)a | Mean age (years) | Female proportion |
---|---|---|---|---|---|---|
Nowomiejska et al22 | Wet AMD (36), healthy subjects (23) | Diagnostic case–control study | n.r. | 59 | Wet AMD 72.0, healthy subjects 68.3 | Wet AMD 0.67, healthy subjects 0.44 |
Alster et al23 | CNV (65), intermediate AMD (57) | Prospective, comparative, clinical study | + | 122 | Median: CNV 77, intermediate AMD 76 | CNV 0.6, intermediate AMD 0.53 |
Preferential hyperacuity perimeter (PHP) Research Group, Goldstein et al6 | CNV (19), geographic atrophy (27)b, intermediate AMD (20)b, early AMD (51)b, health subjects (33) | Diagnostic case–control study | + | 150c | 73.6 (based on 171 patients) | 0.54 (Based on 171 patients) |
Isaac et al24 | CNV (10), intermediate AMD (18), early AMD (22), healthy subjects (15) | Diagnostic case–control study | n.r. | 65 | CNV 71.7, intermediate AMD 66.0, early AMD 67.3, healthy subjects 64.7 | CNV 0.6, intermediate AMD 0.444, early AMD 0.545, healthy subjects 0.533 |
Lai et al25 | CNV (10), late AMD (10)b, health subjects (21) | Diagnostic case–control study | n.r. | 41 | n.r. | n.r. |
Loewenstein et al26 | CNV (32), geographic atrophy (23)b, AMD with high-risk characteristics (HRC) (35)b, early AMD with non-HRC (18)b, healthy subjects (51) | Diagnostic case–control study | + | 159 | 74 | 0.59 |
Loewenstein et al (retrospective)27 | Recent onset CNV (34), intermediate AMD (43) | Diagnostic case–control study | n.r. | 77 | Median 76 | CNV 0.58, intermediate AMD 0.30 (1 unknown) |
Loewenstein et al (prospective)27 | Recent onset CNV (32), intermediate AMD (22) | diagnostic case–control study | + | 54 | Median: CNV 78, intermediate AMD 73.5 | CNV 0.71 (1 unknown), intermediate AMD 0.60 (2 unknown) |
Mathew and Sivaprasad28 | First test: CNV (59), no CNV (41), Second test: CNV (68), no CNV (32) | Prospective cohort study | n.r. | 100 | 80.2 | 0.61 |
Robinson et al29 | Wet AMD (29 eyes), dry AMD (34)b, healthy subjects (27 eyes) | Diagnostic case–control study | n.r. | 90 | Wet AMD 77.7, dry AMD 75.9 | AMD patients 0.56 |
Arimura et al30 | AMD (19; 6 dry type and 13 wet type), idiopathic macular hole (M-hole) (22)b, idiopathic epiretinal membrane (ERM) (39)b, healthy subjects (51) | Diagnostic case–control study | n.r. | 131 | AMD 67.6, M-hole 63.1, ERM 64.1, healthy subjects 68.0 | AMD 0.16, M-hole 0.46, ERM 0.59, healthy subjects 0.57 |
Klatt et al31 | Classic CNV (35), occult CNV (38), intermediate AMD (13)b, retinopathia centralis serosa (RCS) (11)b, epiretinal gliosis (13)b, macular foramen (23)b, healthy subjects (20) | Diagnostic case–control study | n.r. | 153 | Occult CNV 75.9, classic CNV 74.2, intermediate AMD 72.4, RCS 41.3, epiretinal Gliosis 71.7, macular foramen 67.9 | Occult CNV 0.58, classic CNV 0.57, intermediate AMD 0.54, RCS 0, epiretinal gliosis 0.62, macular foramen 0.82 |
Kampmeier et al32 | Classic CNV (11), occult CNV (25), retinal pigment epithelium elevation (9), non-neovascular AMD (95)b, healthy subjects 34 | Diagnostic case–control study | + | 174 | Median: CNV+non-neovascular AMD 68 | CNV+non-neovascular AMD 0.49 |
Abbreviation: n.r., not reported.
Includes all subsets studied.
Excluded from analysis.
Patients (179) were enrolled in the study. Mean age and female proportion were reported for 171 patients. For 150 patients results were reported.